Portal de Periódicos da CAPES

A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL

2017; Elsevier BV; Volume: 131; Issue: 9 Linguagem: Inglês

10.1182/blood-2017-06-792333

1528-0020

Natalie Dimier, Paul Delmar, Carol Ward, Rodica Morariu-Zamfir, Günter Fingerle‐Rowson, Jasmin Bahlo, Kirsten Fischer, Barbara Eichhorst, Valentin Goede, Jacques J. M. van Dongen, Matthias Ritgen, Sebastian Böttcher, Anton W. Langerak, Michael Kneba, Michael Hallek,

Lymphoma Diagnosis and Treatment

Key Points Meta-analysis of 3 randomized clinical trials shows a statistically significant relationship between treatment effects on PFS and MRD. Meta-regression model supports use of MRD as a primary end point in clinical trials of chemoimmunotherapy in CLL.